# Javid J. Moslehi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/javid-j-moslehi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 44,310 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 98 |
| i10-index | 252 |
| Last Known Institution | University of California, San Francisco |
| OpenAlex ID | https://openalex.org/A5019401898 |
| ORCID iD | https://orcid.org/0000-0001-5443-4312 |
| Works | 489 |

## Researcher papers

- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the-2/)
- [Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations](https://scholariq.org/papers/management-of-cardiac-disease-in-cancer-patients-throughout-oncological/)
- [Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society](https://scholariq.org/papers/baseline-cardiovascular-risk-assessment-in-cancer-patients-scheduled-to-receive/)
- [Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy](https://scholariq.org/papers/management-of-acute-myocarditis-and-chronic-inflammatory-cardiomyopathy/)
- [Recognition and Initial Management of Fulminant Myocarditis](https://scholariq.org/papers/recognition-and-initial-management-of-fulminant-myocarditis/)
- [2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)](https://scholariq.org/papers/2022-esc-guidelines-on-cardio-oncology-developed-in-collaboration-with-the/)
- [A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention](https://scholariq.org/papers/a-genetic-mouse-model-recapitulates-immune-checkpoint-inhibitor-associated/)
- [Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis](https://scholariq.org/papers/cardiomuscular-biomarkers-in-the-diagnosis-and-prognostication-of-immune/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Chemotherapy-induced cardiotoxicity and mitigation](https://scholariq.org/topics/chemotherapy-induced-cardiotoxicity-and-mitigation/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Viral Infections and Immunology Research](https://scholariq.org/topics/viral-infections-and-immunology-research-2/)

## Researcher university

- [University of California, San Francisco](https://scholariq.org/institutions/university-of-california-san-francisco/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.